| Systematic (IUPAC) name | |
|---|---|
| Nonasodium (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6- |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Routes | Subcutaneous |
| Pharmacokinetic data | |
| Half-life | 80-130 hours |
| Identifiers | |
| CAS number | 149920-56-9 |
| ATC code | None |
| PubChem | CID 3083444 |
| ChemSpider | 2340656 |
| Chemical data | |
| Formula | C38H55Na9O49S7 |
| Mol. mass | 1727.17683 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Idraparinux sodium is an anticoagulant medication in development by Sanofi-Aventis.[1]
It has a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours), which means that the drug should only need to be injected once a week.
As of July 2007[update], it has completed the Phase III clinical trial AMADEUS.
Idraparinux selectively blocks coagulation factor Xa.[2]
See Heparin: Mechanism of anticoagulant action for a comparison of the mechanism of heparin, low-molecular-weight heparins, fondaparinux and idraparinux.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||